論文

査読有り
2020年

Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats.

Biological & pharmaceutical bulletin
  • Ryo Kondo
  • ,
  • Ayuki Nakano
  • ,
  • Daiki Asano
  • ,
  • Akane Morita
  • ,
  • Shiho Arima
  • ,
  • Asami Mori
  • ,
  • Kenji Sakamoto
  • ,
  • Tohru Nagamitsu
  • ,
  • Tsutomu Nakahara

43
5
開始ページ
859
終了ページ
863
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1248/bpb.b19-01065

Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine whether the abnormal vascular growth occurs in a manner dependent on the degree of the vascular defects. Vascular defects of two different degrees were created in the retina by subcutaneously treating neonatal rats with the VEGF receptor (VEGFR) tyrosine kinase inhibitor KRN633 on postnatal day (P) 4 and P5 (P4/5) or P7 and P8 (P7/8). The structure of the retinal vasculature changes was examined immunohistochemically. Prevention of vascular growth and regression of some preformed capillaries were observed on the next day, after completion of each treatment (i.e., P6 and P9). The vascular regrowth occurred as a result of eliminating the inhibitory effect on the VEGFR signaling pathway. KRN633 (P4/5)-treated rats exhibited a retinal vasculature with aggressive intravitreal neovascularization on P21. On the other hand, the appearance of tortuous arteries is a representative vascular pathological feature in retinas of KRN633 (P7/8)-treated groups. These results suggest that an interruption of the retinal vascular development at different time points induces different vascular pathological features in the retina. Pharmacological agents targeting the VEGF signaling pathway are useful for creating an abnormal retinal vasculature with various pathological features in order to evaluate the efficacy of anti-angiogenic compounds.

リンク情報
DOI
https://doi.org/10.1248/bpb.b19-01065
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32378561
ID情報
  • DOI : 10.1248/bpb.b19-01065
  • PubMed ID : 32378561

エクスポート
BibTeX RIS